drugset / Trial / NCT05983965
Study of Tazemetostat in Lymphoid Malignancies
Phase 1
Terminated
6 enrolled
University of Alabama at Birmingham
Epizyme, Inc. · collabRobert Award · collab
NaSingle-groupOpen-labelTreatment
Summary
Tazemetostat is an oral EZH2 inhibitor which has been FDA approved for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment option. We propose a study to evaluate the safety of tazemetostat in relapsed / refractory peripheral T-cell lymphoma.
Timeline
- Start
- 2024-09-05
- Primary completion
- 2026-03-06
- Completion
- 2026-03-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tazemetostat | Small molecule | — | Oral |